We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fed Conditions

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00776022
First Posted: October 20, 2008
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ohm Laboratories, Inc.
Information provided by:
Ranbaxy Inc.
  Purpose
An open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability study comparing Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) with Zyrtec® Cetirizine Hydrochloride, 10 mg tablet of Pfizer Labs (Division of Pfizer Inc.) in healthy, adult, human subjects under fed condition

Condition Intervention
Healthy Drug: Cetirizine Hydrochloride 10 mg tablet

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: An Open Label, Randomized, Single-center, Single-dose, Two-treatment, Two-period, Crossover Bioavailability Study Comparing Cetirizine Hydrochloride 10 mg Tablet of Ohm Laboratories Inc. (A Subsidiary of Ranbaxy, Inc) With Zyrtec® Cetirizine Hydrochloride, 10 mg Tablet of Pfizer Labs (Division of Pfizer Inc.) in Healthy, Adult, Human Subjects Under Fed Condition

Resource links provided by NLM:


Further study details as provided by Ranbaxy Inc.:

Primary Outcome Measures:
  • Evaluation of Bioequivalence between ranbaxy acetaminophen 650 mg extended release gelcaps and Tylenol® Arthritis Pain extended release caplets (containing acetaminophen 650 mg) of Mc Neil-PPC Inc.,under fed conditions

Enrollment: 32
Study Start Date: April 2005
Study Completion Date: June 2005
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Cetirizine Hydrochloride 10 mg tablet of Ohm Laboratories
Drug: Cetirizine Hydrochloride 10 mg tablet
Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
Active Comparator: 2
Cetirizine Hydrochloride 10 mg tablet of Pfizer Labs
Drug: Cetirizine Hydrochloride 10 mg tablet
Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions

Detailed Description:

The study was conducted as an open label, randomized, single-center, single-dose, two-treatment, two-period, crossover bioavailability of the test formulation of cetirizine hydrochloride tablet of Ohm Laboratories Inc. (A subsidiary of Ranbaxy, Inc) containing 10 mg cetirizine hydrochloride study comparing to the marketed product, Zyrtec®, containing 10 mg of cetirizine hydrochloride of Pfizer Labs (Division of Pfizer Inc.), in healthy, adult, human, subjects under fed condition.

Safety measures were performed throughout the study and included a physical examination, laboratory evaluation, and measurement of vital signs.

A total of 32 subjects were randomized to receive single oral dose of cetirizine hydrochloride 10 mg tablet and 29 subjects completed both the periods of the study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • - Aged 18-50 years.
  • Were within 18 to 29.9 kilograms/m2 per the BMI (Determination of Body Mass Index).
  • Had voluntarily given written informed consent to participate in this study.
  • Were of normal health as determined by medical history and physical examination of the subjects performed within 30 days prior to the commencement of the study.
  • Blood chemistry, hematology, and urinalysis tests performed within 30 days prior to the start of the study must be within clinically acceptable limits upon evaluation by the Investigator.
  • Subjects must have screening and check-in (each period) blood pressure and pulse rate within the protocol specified ranges.
  • If female and of childbearing potential, the subject was counseled on the importance of not becoming pregnant before or during the study, and the subject had a negative pregnancy test at the pre-treatment visit.

Exclusion Criteria:

  • - History of clinically significant organ-system (cardiovascular, neurological, hepatic, hematopoietic, pulmonary, endocrine, or gastrointestinal) disorders, or ongoing infectious diseases.
  • history of alcohol abuse or drug addiction requiring treatment within the last 12 months.
  • Presence or history of renal impairment or chronic liver disease.
  • History of jaundice (yellowing of the skin or whites of the eyes).
  • Participation in an investigationaldrug study or donation of blood within 30 days prior to the start of the study.
  • Known allergy or sensitivity to cetirizine (Zyrtec®), or to related drugs such as hydroxyzine (Vistaril® or Ataraxl®).
  • Prescription drug use (excluding hormonal contraceptives) within 14 days prior to drug administration, each period. Subject is taking macrolide antibiotics, such as erythromycin, azithromicin, ketoconazole, or related drugs.
  • Ingestion of grapefruit juice or grapefruit-containg products within 72 hours prio to drug administration, each period.
  • Alcohol consumption 24 hours prior to drug administration, each period.
  • Caffeine or xanthine consumption for at least 10 hours prior to drug administration, each period.
  • Female subjects who are pregnant or nursing.
  • Positive HIV 1, Hepatitis B surface antigen, and urine screen for drugs of abuse within 30 days prior to the start of the study.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00776022


Locations
United States, Maryland
Bioanalytical Systems, Inc
Baltimore, Maryland, United States, 21201
Sponsors and Collaborators
Ranbaxy Laboratories Limited
Ohm Laboratories, Inc.
  More Information

Additional Information:
Responsible Party: Dr. Tausif Monif, Ranbaxy Laboratories Limited
ClinicalTrials.gov Identifier: NCT00776022     History of Changes
Other Study ID Numbers: 11849
First Submitted: October 17, 2008
First Posted: October 20, 2008
Last Update Posted: March 2, 2010
Last Verified: March 2010

Keywords provided by Ranbaxy Inc.:
Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions

Additional relevant MeSH terms:
Cetirizine
Anti-Allergic Agents
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs